1. Home
  2. Companies
  3. ATX
  4. Material Events

Amplia Therapeutics (ASX:ATX) — Material Events

ASX:ATX · 11 articles in the last 12 months · 100% assessed

Click a band to jump to that tier

Major 1 article Significant 10 articles Not Assessed 0 articles
Major ≥90 Significant 75–89 Notable 50–74 Routine <50 Not assessed
Significant Score 75–89
10
Amplia’s Narmafotinib Shows Survival Gains and Manufacturing Scale-UpMedium
Amplia Therapeutics reports positive ACCENT trial results, GMP production milestone, CFO appointment, and $27.9M cash at March 2026 quarter end
28 Apr 2026 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Raises $27.6M Amid Promising Pancreatic Cancer Trial ResultsMedium
Amplia Therapeutics reports $4.18M half-year loss, raises $27.6M to advance promising pancreatic cancer drug trials
27 Nov 2025 ·Appendix 4D and Half Year Financial Report ·85
Amplia Therapeutics Advances Pancreatic Cancer Drug with Positive Trial Data and $27.5M RaiseMedium
Amplia Therapeutics advances pancreatic cancer drug narmafotinib with positive trial data and $27.5M capital raise
29 May 2026 ·Annual Report ·85
Amplia’s Pancreatic Cancer Drug Shows 35% Response Rate, FDA Backs Dose PlanMedium
Amplia Therapeutics reports strong clinical trial progress, FDA support, patent grant, and solid cash position
30 Jan 2026 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Advances Pancreatic Cancer Drug with New Trial and Patent WinMedium
Amplia Therapeutics reports encouraging narmafotinib trial progress, key patent allowance, and A$27.5M capital raise
29 Oct 2025 ·Quarterly Activities and Cash Flow Report ·85
Amplia Expands Narmafotinib Trials with Lilly in $31B Lung Cancer MarketMedium
Amplia and Lilly collaborate on clinical trial combining narmafotinib and olomorasib for NSCLC
4 Aug 2026 ·Clinical Trial Collaboration Announcement ·85
Amplia Advances Narmafotinib Trials and Board with $24M Cash PositionMedium
Amplia Therapeutics advances narmafotinib trials, board renewal, and IP expansion with A$24M cash
29 July 2026 ·Quarterly Activities and Cash Flow Report ·85
Amplia Therapeutics Gains FDA Backing for Pivotal Pancreatic Cancer TrialMedium
Amplia Therapeutics Secures Positive FDA Feedback on Phase 2b/3 Pancreatic Cancer Trial
20 Nov 2025 ·ASX Release ·80
Amplia Therapeutics Advances Narmafotinib with Phase 2b Daily Dosing Trial in Pancreatic CancerMedium
Amplia Therapeutics launches Phase 2b trial of narmafotinib for pancreatic cancer with new daily dosing
19 May 2026 ·Clinical Trial Initiation ·80
Amplia and ANZGOG Launch PRROSE Trial Targeting Resistant Ovarian CancerMedium
Amplia Therapeutics and ANZGOG launch ovarian cancer trial for narmafotinib
8 May 2026 ·Clinical Trial Announcement ·75
Not Assessed Low Score, or missing data
0

No articles in this tier for the last 12 months.